Ignite Creation Date:
2024-05-05 @ 7:12 PM
Last Modification Date:
2024-10-26 @ 9:45 AM
Study NCT ID:
NCT00621153
Status:
COMPLETED
Last Update Posted:
2010-03-23
First Post:
2008-01-24
Brief Title:
Candesartan Effect in Second Stage Arterial Hypertension
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Open-label Randomised 2-Arm Parallel Group Multicentre 8-week Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 125 mg Combination Therapy in Comparison With Candesartan 16 mg Monotherapy in Hypertensive Adults
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CAESAR
Brief Summary:
To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either candesartan cilexetilHCT combination therapy or candesartan cilexetil monotherapy regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None